First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer – Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110)
Titel:
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer – Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110)
Auteur:
Stahler, Arndt Modest, Dominik P. Fischer von Weikersthal, Ludwig Kaiser, Florian Decker, Thomas Held, Swantje Graeven, Ullrich Schwaner, Ingo Denzlinger, Claudio Schenk, Michael Kurreck, Annika Heinrich, Kathrin Gießen-Jung, Clemens Neumann, Jens Kirchner, Thomas Jung, Andreas Stintzing, Sebastian Heinemann, Volker